ResMed Analyst Price Targets

ResMed Inc

RMDNYSE

$251.76

1.590.64%

Dern. MÀJ: Oct 29, 12:09 PM

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Dividendes Comparer Options Rapport sur les stocks

Résultats: Annonce des résultats Q1 2027 après la fermeture du marché aujourd'hui

Conférence téléphonique: Conférence téléphonique prévue aujourd'hui à 4:30 PM

Cliquez pour voir la webdiffusion

ResMed Analyst Price Targets

Wall Street analyst price targets and consensus rating for ResMed (RMD).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

6Buy

7Hold

1Sell

Consensus RatingNeutral# Analysts14Avg. Consensus PT$246Upside to Avg. PT-2.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	RBC Capital	Craig Wong-Pan	Upgrade	Sector Perform→Outperform	$244→$262
Aug 31, 2026	Keybanc	Brett Fishbin	PT Raise	Overweight	$255→$267
Aug 19, 2026	Rothschild & Co	Jackson Philips	Initiate	Neutral	$230
Aug 7, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Sector Perform	$234→$244
Aug 7, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$233→$225
Aug 7, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$260→$255
Aug 7, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$225→$215
Jul 15, 2026	Mizuho	Anthony Petrone	PT Cut	Outperform	$235→$220
Jul 13, 2026	Citigroup	Laura Sutcliffe	Downgrade	Buy→Neutral	$270→$235
Jul 10, 2026	Jefferies	Matthew Taylor	PT Cut	Hold	$240→$225
Jul 8, 2026	RBC Capital	Craig Wong-Pan	PT Cut	Outperform	$321→$276
Jul 8, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$227→$225
Jun 22, 2026	Keybanc	Justin Patterson	PT Cut	Overweight	$290→$266
Jun 17, 2026	Morgan Stanley	David Bailey	Downgrade	Overweight→Equal-Weight	$286→$230
Jun 15, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$340→$270
May 1, 2026	RBC Capital	Craig Wong-Pan	PT Raise	Outperform	$314→$321
May 1, 2026	Wells Fargo	Nathan Treybeck	PT Cut	Equal-Weight	$270→$227
Apr 27, 2026	Keybanc	Brett Fishbin	PT Cut	Overweight	$302→$290
Apr 15, 2026	JP Morgan	David Low	Reinstates	Overweight	—
Apr 9, 2026	Citigroup	Laura Sutcliffe	PT Cut	Buy	$345→$340

Analyst Ratings News

PRO
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

RBC Capital analyst Craig Wong-Pan upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $244 to $262.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $255 to $267.

Benzinga Newsdesk

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.

Benzinga Newsdesk

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $260 to $255.

Benzinga Newsdesk

ResMed Inc

ResMed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

ResMed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

People Also Watch

People Also Watch

ResMed Inc

ResMed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PROKeybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRORothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRORBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PROPiper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PROKeybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

ResMed Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PROKeybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRORothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRORBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PROPiper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PROKeybanc Maintains Overweight on ResMed, Lowers Price Target to $255

People Also Watch

People Also Watch

PRO
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

PRO
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $262

PRO
Keybanc Maintains Overweight on ResMed, Raises Price Target to $267

PRO
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

PRO
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

PRO
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

PRO
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255